About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$14.60
Change (%) Stock is Up 0.04 (0.27%)
Volume1,016,721
Data as of 01/18/19 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $14.60 with a 52 week high of $29.62 and a 52 week low of $8.60.

Recent News

Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection - 01/07/19
Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch SAN CARLOS, Calif., Jan. 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study... More»
Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference - 01/04/19
SAN CARLOS, Calif., Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live presentation at the 37th Annual J.P. Morgan Healthca... More»
Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology - 01/04/19
Represents Key Reimbursement Milestone In Line with Planned Clinical Launch SAN CARLOS, Calif., Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in non-invasive genetic testing and cell-free DNA, today announced the assi... More»
Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman - 01/02/19
Proven Commercial Execution Selected for CEO Role; Seasoned Operational Expertise Selected for COO Role SAN CARLOS, Calif., Jan. 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of ce... More»
Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response - 12/06/18
Study Demonstrates Utility of Assay in Neoadjuvant and Adjuvant Treatment Settings SAN CARLOS, Calif., Dec. 6, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, presente... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools